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Summary Generalized epilepsy with febrile seizures plus (GEFS+) is an inherited
epileptic syndrome with a marked clinical and genetic heterogeneity. Here we report
the molecular characterization of a large pedigree with a severe clinical form of
GEFS+. Genetic linkage analysis implied the involvement of the FEB3 in the disease
phenotype of this family (parametric two-point lod-score of 2.2). Sequencing of the
SCN1A gene revealed a novel aspartic acid for glycine substitution at position 1742 of
this sodium channel subunit. The amino-acid replacement lies in the pore-forming
region of domain IV of SCN1A. Our observations are consistent with the genotype—
phenotype correlation studies suggesting that mutations in the pore-forming loop of
SCN1A can lead to a clinically more severe epileptic syndrome.
# 2004 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.Introduction
Generalized seizures during febrile episodes (febrile
seizures, FS) occur in 2—5% of children under six.1 Of
these, about 5% develop non-febrile seizures and/or
epilepsy later in life (denoted as FS+).2 Family
studies indicate an important genetic susceptibility
to FS3 and have led to the identification of four
linked loci: FEB1 at 8q13-q21,4 FEB2 at 19p13.3,5
FEB3 at 2q23-q24,6 and FEB4 at 5q14-q15.7 Scheffer
and Berkovic8 defined an autosomal dominant form
of FS+ denoted generalized epilepsy with febrile* Corresponding author. Tel.: +44 20 7679 5049;
fax: +44 20 7679 5052.
E-mail address: a.ruizlin@ucl.ac.uk (A. Ruı´z-Linares).
1059-1311/$ — see front matter # 2004 BEA Trading Ltd. Published
doi:10.1016/j.seizure.2004.12.007seizures plus (GEFS+) to include individuals
with various types of seizures (partial, absences,
astatic). Mutations at four genes resulting in GEFS+
have recently been identified: the type-1 voltage-
gated sodium-channel subunits b (SCN1B) and a
(SCN1A),9,10 the gamma-2 subunit of the gamma-
aminobutyric acid receptor (GABRG2)11 and the
type-2 voltage-gated sodium-channel subunit a
(SCN2A).12 Mutations at these genes account for
less than 10% of families with GEFS+, indicating
a further genetic heterogeneity of this epileptic
syndrome.
Here we report the genetic characterization of a
large South American family including several indi-
viduals with a severe form of GEFS+. Linkage ana-
lysis to known FEB genes/regions was consistentby Elsevier Ltd. All rights reserved.
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exons of the SCN1A gene revealed a c.5213A>G
mutation leading of the substitution of an aspartic
acid for a glycine at position 1742 of the SCN1A
protein. This mutation is located in the highly con-
served pore region of domain 4 of this sodium
channel subunit. Previous studies have shown that
de novo mutations in this domain of the SCN1A
protein are often associated with severe myoclonic
epilepsy of infancy (SMEI), an intractable form of
epilepsy that has been proposed as part of the GEFS+
spectrum.13Patients and methods
Study pedigree
The index case of the family (Fig. 1) is a patient
attending the pediatric neurology service of Hospi-
tal Universitario San Vicente de Paul (Medellin,
Colombia). The pedigree was extended focusing
on a history of seizures in relatives of the index
case. All available individuals with a positive history
underwent a full neurological examination and the
characteristics of the seizures evaluated by inter-
viewing relatives and reviewing available clinical
records. Seizures were categorized according to
international classifications.14 Blood samples were
collected from all available individuals and genomic
DNA obtained using the QIAGEN DNA extraction kit
following the manufacturer’s instructions. The
Bioethics Committee of Universidad de Antioquia
approved this research project and all participants
provided their informed consent.Table 1 Clinical features of the patients in the family stu
Individual Age FS onset/offset FS episodes AFS onset/
II 1 53 6m/7y ### —
II 6 59y 6m/9y N.I. 33y/54y
III 3 36y 3m/N.I. 15 N.I./ongoi
III 4 19y 6m/7y ### 7y/19
III 5 27y 6m/8y ### 13y/21y
III 10 30y 2y/ongoing ### 30y/ongoi
III 13 23y 9m/2y 15 2y/ongoin
III 14 7m 4m/7m 4 —
III 16 28y 6m/ongoing 20 8y/ongoin
IV 1 11y 5m/ongoing 20 —
IV 3 4y 9m/3y 10 —
IV 6 10y 6m/3y >20 —
IV 7 3y 3m/ongoing ### 3y/ongoin
FS: febrile seizures, AFS: afebrile seizures, GTCS: generalized toni
countless, N.I.: no information. Individuals shown in bold are deceGenotyping and linkage analysis
The following six microsatellite markers were gen-
otyped (as described) in order to assess linkage to
known FEB loci and GEFS+ genes: D8S530 for FEB1,4
D19S177 for FEB2,5,15 D2S382 for FEB3/SCN1A,16
D5S644 for FEB4,7 D19S425 for SCN1B,9 and
D5S1403 for GABRG2.11 FEB3/SCN1A was followed-
up by genotyping two additional markers (D2S2330
and D2S2157).16,17 PCR reactions were performed in
an MJ Research (DYADTM) thermocycler in a final
volume of 15 mL with 30 ng of DNA, 0.3 mM of each
primer and 1 of HotStart TaqTM Master Mix (QIA-
GEN). Amplification products were examined on an
ABI-377 DNA sequencer (Applied Biosystems) and
runs analyzed with GENESCAN and GENOTYPER soft-
ware (Applied Biosystems). Two-point lod-scores
were calculated using the MLINK program18 assum-
ing an autosomal dominant mode of inheritance
with 96% penetrance (assumed from the pedigree),
a mutated allele frequency of 0.0001 and equal
allele frequencies at the marker loci. All individuals
with a diagnosis of FS or GEFS+ were considered as
affected in the analyses and a phenocopy rate of 3%
was assumed.19
Mutation screening
All exons of the SCN1A gene were amplified using the
primers and PCR conditions reported by Malacarne
et al.20 PCR products were sequenced using the Big-
Dye Deoxy Terminator Cycle sequencing kit (Applied
Biosystems) on an ABI-377 DNA sequencer following
the manufacturer’s instructions. Mutation screening
was carried out by restriction enzyme digestion of
PCR products with Tsp45I (New England Biolabs) atdied.
offset AFS episodes Seizure type Mental
retardation
— GTCS No
N.I. PS No
ng 20 GTCS No
>20 GTCS Yes
### GTCS Yes
ng ### PS Yes
g ### GTCS Yes
— GTCS No
g ### PS No
— GTCS No
— GTCS, myoclonic No
— GTCS No
g ### Myoclonic, astatic Yes
c-clonic seizure, PS: partial seizure, y/m: years/months, ###:
ased.
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Figure 1 Pedigree of the family studied. Filled symbols indicate individuals with FS+, symbols with dots indicate individuals with FS and clear symbols represent
unaffected individuals. Squares: males, circles: females. Numbers under the symbols refer to allele sizes at the loci examined. The nucleotide change leading to the D1742G
substitution in SCN1A is shown as G (mutant) or A (wild-type).
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Table 2 Two-point lod-scores for markers at FS loci (FEB) and GEFS+ genes.
Marker Locus/gene Recombination fraction
0 0.1 0.2 0.3 0.4
D8S530 FEB 1 4.09 1.53 0.64 0.25 0.08
D19S177 FEB 2 2.01 0.68 0.34 0.20 0.11
D2S382 FEB 3/SCN1A 2.24 1.83 1.39 0.92 0.44
D5S644 FEB 4 2.19 0.04 0.42 0.47 0.32
D19S425 SCN1B 3.62 1.51 0.76 0.34 0.11
D5S1403 GABR G2 6.70 2.59 1.27 0.57 0.1837 8C overnight. Digestion products were then
examined on 3% agarose gels.Figure 2 Mutation screening of exon 26 of SCN1A. (A)
Partial nucleotide sequence of the exon showing the
heterozygous A>G substitution observed in a patient
sample (indicated by the letter R). (B) Restriction diges-
tion of exon 26 with Tsp45I. The presence of the
c.5213A>G mutation leads to the destruction of the
restriction site. Labels of lanes refer to the individuals
examined as in the pedigree of Fig. 1.Results
Clinical findings
The index case is a patient aged 3 that since three
months of age presents myoclonic astatic seizures
(up to four per week) that have not responded to
treatment with valproic acid and phenobarbital.
The patient presents mental retardation and has a
normal interictal EEG and CT scan. Pedigree exten-
sion revealed a history of seizures in 12 relatives of
the index case, 9 of which are alive (Fig. 1). The
main clinical features of the affected individuals in
this pedigree are summarized in Table 1. All cases
had a history of febrile seizures with the first epi-
sode occurring between 3 months and 2 years. The
nine patients currently over six years of age have
presented episodes of febrile seizures after that
age. Eight of these individuals also presented non-
febrile seizures, usually starting after age six. The
most common seizures type is generalized tonico-
clonic, although three patients presented complex
partial seizures. Response to treatment was usually
poor and most patients had a history of countless
seizures, with the most recent episode ranging
between 19 and 54 years of age. Mental retardation
was present in four cases. Available interictal EEGs
are normal.
Linkage analysis
Genotype information was obtained for 20 indivi-
duals including the nine living affecteds. Signifi-
cantly negative lod-scores (<2) were observed
at theta 0 for all markers tested with the exception
of D2S382 at FEB3/SCNA1, which showed a maxi-
mum lod score of 2.24 (Table 2). Genotypes at two
additional markers in FEB 3 (D2S2330 and D2S2157)
resulted in maximum lod-scores (at 0 recombination
fraction) of 2.83 and 1.19, respectively. All affectedindividuals except IV 3 carry a haplotype character-
ized by alleles 147, 166 and 167 at markers D2S2157,
D2S382 and D2S2330, respectively (Fig. 1). A recom-
bination event between markers D2S2157 and
D2S382 was observed in individual III 15 who is
unaffected but carries the disease-associated allele
147 at locus D2S157.
Mutation identification
Sequencing of SCN1A exons in two carriers of the
disease-associated haplotype (II 6 and III 10)
revealed a heterozygous A>G substitution in exon
26 at position 5213 of the SCNA1mRNA (c.5213A>G,
Fig. 2). This base change destroys a recognition site
for enzyme Tsp45I. Restriction enzyme digestion of
exon 26 PCR products showed that the c.5213A>G
base change is present in the individuals that were
considered affected, except for IV 3, which there-
fore represents a FS phenocopy. This DNA mutation
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Figure 3 Aminoacid sequence alignment of the loop between segments S5 and S6 in domain D-IV of human neuronal
sodium channels. The aspartate residue (D) at position 1742 that is substituted by glutamate in the GEFS+ family
examined is underlined in bold.was not observed in 60 unaffected controls from the
same population. The c.5213A>G substitution leads
to the replacement of an aspartate for a glycine at
position 1742 of SCNA1 (D1742G). This amino-acid
lies in the evolutionarily conserved pore-forming
loop between segments S5 and S6 of domain IV in
the SCNA1 channel (Fig. 3).
Discussion
In the past few years, four genes have been iden-
tified that when mutated lead to the development
of autosomal dominant GEFS+: SCN1B (GEFS+1),
SCN1A and SCN2A (GEFS+2), and GABRG2 (GEFS+3).
Thus far, nine amino-acid substitutions leading to
GEFS+2 have been identified in SCNA1.10,13,21,22
Three of these mutations have been shown to
result in hyperexitability of the sodium channel,23
indicating that the dominance of these alleles is
related to a gain of function. Recently, mutations
in SCNA1 have also been shown to underlie
SMEI.24,25 Consistent with these molecular find-
ings, it had been suggested that SMEI could con-
stitute the most severe form of the GEFS+ clinical
spectrum.13 The initial SMEI-causing mutations
identified in SCNA1 were nonsense or splice-site
substitutions leading to the production of a trun-
cated sodium channel and suggesting that the
severity of the phenotype related to haploinsuffi-
ciency.24 More recently, a number of SCNA1 mis-
sense mutations have been identified in SMEI
patients.25—28 Interestingly, most of these amino-
acid substitutions are located in the functionally
critical pore region of SCNA1 (S4—S6) and could
therefore have a major impact on the kinetic
properties of this sodium channel.25
The molecular genetic characterization of the
South American family examined here evidenced
linkage to SCN1A and led to the identification of a
novel D1742G mutation in the loop between seg-
ments S5 and S6 in domain IV of this sodium chan-
nel. The findings in this pedigree are consistent
with the view that aminoacid substitutions in the
pore region of SCNA1 can lead to a severe epileptic
phenotype. This family includes several patients
with marked clinical manifestations. The indexcase has astatic epilepsy, while other family mem-
bers present frequent seizure episodes that have
continued into adulthood and that show poor
response to treatment. Several individuals also
have mental retardation, although this could
relate to the high frequency of epileptic episodes.
Interestingly, although most affected family mem-
bers have severe clinical manifestations, some
individuals carrying the D1742G mutation show a
milder phenotype (Fig. 1; Table 1). Most notably,
the sib of the severely affected index case, pre-
sents only mild clinical manifestations (i.e. FS).
This suggests that genetic and/or environmental
modifiers can have an important impact on the
phenotypic expression of the D1742G mutation.
Identification of these modifying factors will
require the study of a large number of GEFS+
patients that are carriers of this mutation. In con-
clusion, our findings are consistent with proposed
genotype—phenotype correlations based on ana-
lyses of GEFS+ and SMEI patients but also underline
the highly variable phenotypic expression of SCN1A
mutations.Acknowledgments
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